RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 120 filers reported holding RA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 4.66 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $804,000 | -67.9% | 16,750 | -68.7% | 0.00% | -50.0% |
| Q4 2019 | $2,507,000 | +198.8% | 53,436 | +50.2% | 0.00% | +100.0% |
| Q3 2019 | $839,000 | -46.4% | 35,579 | -31.7% | 0.00% | 0.0% |
| Q2 2019 | $1,565,000 | -64.7% | 52,090 | -73.7% | 0.00% | -66.7% |
| Q1 2019 | $4,428,000 | +266.6% | 197,741 | +197.7% | 0.00% | +200.0% |
| Q4 2018 | $1,208,000 | -64.1% | 66,433 | -64.3% | 0.00% | 0.0% |
| Q3 2018 | $3,364,000 | +94.8% | 186,046 | +7.1% | 0.00% | – |
| Q2 2018 | $1,727,000 | +44.0% | 173,757 | -23.1% | 0.00% | -100.0% |
| Q1 2018 | $1,199,000 | +435.3% | 225,952 | +755.1% | 0.00% | – |
| Q4 2017 | $224,000 | -39.5% | 26,425 | +3.6% | 0.00% | – |
| Q3 2017 | $370,000 | -27.2% | 25,504 | -6.1% | 0.00% | – |
| Q2 2017 | $508,000 | +29.6% | 27,165 | +47.0% | 0.00% | – |
| Q1 2017 | $392,000 | -9.3% | 18,483 | -35.5% | 0.00% | – |
| Q4 2016 | $432,000 | – | 28,635 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |